Rubin, K. M. (2015). Understanding immune checkpoint inhibitors for effective patient care. Clinical Journal of Oncology Nursing, 19 (6), 709–717. doi:10.1188/15.CJON.709-717 Schreiber, R. D., Old, L. J. e Smyth, M. J. (2011). Cancer immunoediting: Integrating immunity’s role in cancer suppression and promotion. Science, 331(6024), 1565–1570. doi:10.1126/science.1203486 Scott, A. M., Allison, J. P. e Wolchok, J. D. (2012). Monoclonal antibodies in cancer therapy. Cancer Immunity, 12, 14. Shah, J. e Welsh, S. J. (2014). The clinical use of granulocyte- colony stimulating factor. British Journal of Hospital Medicine, 75 (2), C29–C32. doi:10.12968/hmed.2014.75.Sup2.C29 Shelake, S., Eslin, D., Sutphin, R. M., Sankpal, U. T., Wadwani, A.. Kenyon, L.E., . . . Basha, R. (2015). Combination of 13 cis-retinoic acid and tolfenamic acid induces apoptosis and effectively inhibits high-risk neuroblastoma cell proliferation. International Journal of Developmental Neuroscience, 46, 92–99. doi:10.1016/ ijdevneu.2015.07.012 Shore, N. (2015). Advances in the understanding of cancer immunotherapy. BJUI International, 116, 321–329. doi:10.1111/ bju.12692. Extraído de: www.bjui.org Smith, M. (2016). Molecularly targeted therapies and biotherapeutics. Em P.A. Pizzo e D. G. Poplack (Eds.), Principles and practice of pediatric oncology (7 a ed., pp. 316–347). Filadélfia, PA: Wolters Kluwer. Speleman, F., Park, J. R. e Henderson, T. O. (2016). Neuroblastoma: A tough nut to crack. American Society of Clinical Oncology Educational Book, 35, e548–e557. doi:10.14694/EDBK_159169 Stevenson, J. G., Popovian, R., Jacobs, I., Hurst, S. e Shane, L. G. (2017). Biosimilars: Practical considerations for pharmacists. Annals of Pharmacotherapy, 51 (7), 590–602. doi:10.1177/1060028017690743 Stieglitz, E., Ward, A. F., Gerbing, R. B., Alonzo, T. A., Arceci, R. J., Liu, Y. L., . . . Cooper, T. M. (2015). Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children’s Oncology Group. Pediatric Blood Cancer, 62 (4), 629–636. doi:10.1002/pbc.25342 Suck, G., Linn, Y. C. e Tonn, T. (2016). Natural killer cells for therapy of leukemia. Transfusion Medicine and Hemotherapy, 43 (2), 89–95. doi:10.1159/000445325 Suryadevara, C. M., Gedeon, P. C., Sanchez-Perez, L., Verla, T., Alvarez- Breckenridge, C., Choi, B. D., . . . Sampson, J. H. (2015). Are BiTEs the “missing link” in cancer therapy? OncoImmunology, 4 (6), e1008339. doi:10.1080/2162402X.2015.1008339 Tarlock, K. e Meshinchi, S. (2015). Pediatric acute myeloid leukemia. Pediatric Clinics of North America, 62 (1), 75–93. doi:10.1016/j. pcl.2014.09.007 Tirkes, T., Hollar, M. A., Tann, M., Kohli, M. D., Akisik, F. e Sandrasegaran, K. (2013). Response criteria in oncologic imaging: Review of traditional and new criteria. Radiographics, 33, 1323–1341. doi:10.1148/rg.335125214
Traynor, K. (2017). FDA quietly ends a major risk management program. Pharmacy Times, 74 (11), 761. doi:10.2146/news170034 Vesely, M. D. e Schreiber, R. D. (2013). Cancer immunoediting: Antigens, mechanisms and implications to cancer immunotherapy. Annals of the New York Academy of Sciences, 1284 (1), 1–5. http://doi. org/10.1111/nyas.12105 Viens, L. J., Henley, S. J., Watson, M., Markowitz, L. E., Thomas, C. C., Thompson, T. D., . . . Saraiya, M. (2016). Human papillomavirus–associated cancers: United States, 2008–2012. MMWR Morbidity and Mortality Weekly Report, 65 (26), 661–666. doi:10.15585/mmwr.mm6526a1 Voss, S. D., Glade-Bender, J., Spunt, S. L., DuBois, S. G., Widemann, B. C., Park, J. R., . . . Weigel, B. (2015). Growth plate abnormalities in pediatric cancer patients undergoing Phase I anti-angiogenic therapy: A report from the Children’s Oncology Group Phase I consortium. Pediatric Blood and Cancer, 62 (1), 45–51. doi:10.1002/pbc.25229 Waddington, S. N., Privolizzi, R., Karda, R. e O’Neill, H. C. (2016). A broad overview and review of CRISPR-Cas technology and stem cells. Current Stem Cell Reports, 2, 9–20. doi:10.1007/s40778-016-0037-5 Weber, J., Yang, J. C., Atkins, M. B. e Disis, M. L. (2015). Toxicities of immunotherapy for the practitioner. Journal of Clinical Oncology, 33 (18), 2092–2099. doi:10.1200/JCO.2014.60.0379 West, H. (2015). Immune checkpoint inhibitors. JAMA Oncology, 1 (1), 115. doi:10.1001/jamaoncol.2015.0137. Extraído de: http:// jamanetwork.com/journals/jamaoncology/fullarticle/2174768 Whittle, S. B., Smith, V., Doherty, E., Zhao, S., McCarty, S. e Zage, P. (2017). Overview and recent advances in the treatment of neurblastoma. Expert Review of Anticancer Therapy, 17 (4), 369–386. doi:10.1080/14737140.2017.1285230 Zhang, L., Scorsone, K., Woodfield, S. E. e Zage, P. E. (2015). Sensitivity
of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition. Cancer Chemotherapy and Pharmacology, 76, 977–987. doi:10.1007/s00280-015-2871-z
Recursos adicionais Huang, M. A., Krishnadas, D. K. e Lucas, K. G. (2015). Cellular and antibody based approaches for pediatric cancer immunotherapy. Journal of Immunology Research, 2015, 675269. Extraído de: http:// doi.org/10.1155/2015/675269 Wujcik, D. (2014). Science and mechanism of action of targeted therapies in cancer treatment . Seminars in Oncology Nursing, 30 (3), 139–146. doi:10.1016/j.soncn.2014.05.002
Capítulo 5. Bioterapia: Princípios e Agentes 149
Powered by FlippingBook